secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2026-08-06T11:03:44+00:00
Accession:  0001453687-26-000100
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics Q2 2026 net income $15.8M; cash $149.3M; Phase 3 AURORA data expected 1Q27
--------------------------------------------------------------------------------

- Net income $15.8M ($0.47 basic EPS) vs $15.9M prior year; R&D expenses $20.4M, G&A $8.7M.
- Cash $149.3M as of June 30, 2026; cash runway into 2028 via up to $150M K2HV credit facility (first $50M funded).
- Phase 3 AURORA trial of Descartes-08 in MG on track; data expected 1Q27, BLA filing mid-2027.
- Phase 2 TRITON myositis data subset expected 1H27; Phase 1/2 HELIOS pediatric JDM data expected 1H27.
- New licensing agreement with WestGene for in vivo CAR-T; Phase 1 trial 2H26 with data 1H27.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000100/0001453687-26-000100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000100/rnac-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001453687-26-000100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer